Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply We thank Boesen and Gøtzsche for recognizing our research efforts and for the opportunity to respond to their letter on our article.1
First and foremost, Boesen and Gøtzsche criticize the article for omitting detailed information on adverse events (AEs) and quality-of-life data. However, we believe the wealth of data this challenging landmark trial generated, if presented in detail, would require more space than is available in our presentation of the main results—the 2 × 2 design required reporting for both psychotherapeutic and medical interventions.1 Therefore, we had planned to publish separate reports on AEs and further secondary outcomes, including quality of life, and they are currently in preparation. We made this clear by stating that the secondary outcomes included those reported in JAMA Psychiatry1 and by referring readers to the publication of the study protocol.2 Although we appreciate the interest in further results, their absence from the current report is not owing to reporting bias.
Philipsen A, Tebartz van Elst L, Graf E. Quality of Life of Adult Patients With Attention-Deficit/Hyperactivity Disorder Taking Methylphenidate—Reply. JAMA Psychiatry. 2016;73(5):534–535. doi:10.1001/jamapsychiatry.2016.0051
Customize your JAMA Network experience by selecting one or more topics from the list below.